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Objective-To find a simple definition of partial remission (PR) in T1D that reflects both residual 
beta-cell function and efficacy of insulin treatment. 
 
Research Design and Methods-275 patients <16 years were followed from onset of T1D. After 1, 
6 and 12 months stimulated C-peptide during a challenge was used as a measure of residual beta-
cell function.   
 
Results-By multiple regression analysis a negative association between stimulated C-peptide and 
HbA1c (-0.21, regression coefficient, p<0.001) and insulin dose (-0.94, regression coefficient, 
p<0.001) was shown. These results suggested the definition of an insulin dose-adjusted HbA1c 
(IDAA1c) as:  HbA1c (%) + [4 x insulin dose (U/Kg/24h)]. A calculated IDAA1c ≤ 9 
corresponding to a predicted stimulated C-peptide > 300 pmol/l was used to define PR. The 
IDAA1c ≤ 9 had a significantly higher agreement (p <0.001) with residual beta-cell function 
than using a definition of HbA1c ≤ 7.5 %. Between 6 and 12 months after diagnosis, using 
IDAA1c ≤ 9 only 1 patient entered PR and  61 PR ended; using  HbA1c ≤ 7.5 % , 15 entered PR 
and 53 ended; using a definition of insulin dose ≤ 0.5 U/kg/24h  5 entered and  66 ended and for 
stimulated C-peptide (>300 pmol/l)  9 entered PR and  49 ended. 
IDAA1c at 6 months has good predictive power for stimulated C-peptide concentrations after 
both 6 and 12 months.  
 
Conclusions-A new definition of PR is proposed including both glycemic control and insulin 
dose. It reflects residual beta-cell function and has a better stability compared with the 
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linically, newly diagnosed type 
1 diabetes is characterized by a 
transient partial remission (PR) 
period (”honeymoon”) starting shortly after 
insulin treatment is initiated and during which 
the patient’s need for exogenous insulin 
treatment declines and in some cases even 
totally disappears, and metabolic control is 
near to optimal. The pathogenesis of this has 
been the subject of discussion (1) but is likely 
to be a combination of two factors: partial β-
cell recovery with improved insulin secretion 
(2) and improvement of peripheral insulin 
sensitivity (3). 
The definition of the PR period has 
varied greatly in the past. Most authors define 
PR as insulin requirements ≤ 0.5U/kg/24h (4-
6). However, it is not useful to define a 
disease state by the treatment applied and 
insulin dose is influenced by a large number 
of other factors. At best, this is reasonable 
when the treatment policy is uniform. This is 
rarely the case even within single centres and 
even less so in a multicenter international 
study. As an extreme consequence of this 
definition, a diabetic patient is considered to 
be in PR when treated with a relatively low 
dose of insulin. To correct for this problem 
others have used the definition as a HbA1c 
close to or within the normal range (7). This 
definition is also influenced by the treatment, 
as increasing the insulin dose lowers the 
HbA1c level.  Furthermore, there is an initial 
time delay from the time of diagnosis of 4-6 
weeks before a new steady state HbA1c can 
be achieved (8). Somewhat more relevant is 
to combine the two definitions, that is, an 
insulin requirement of ≤ 0.5 U/kg/24h in 
combination with HbA1c ≤ 7.5 % (9,10). 
Others have used an even lower limit for 
insulin requirement such as 0.3U/kg/24h (11). 
Combining the two parameters is better than 
using either one alone, but having separate 
limits on each variable still makes the 
definition suffer from the problem that a 
treatment change easily influences the 
classification of a patient  
As another possibility, Komulainen 
(12) used a basal C-peptide level of 100 
pmol/l as an index for residual beta cell 
function . While fasting C-peptide alone may 
be relatively easy to obtain in research centres 
and correlates with stimulated C-peptide it is 
insufficient for detecting dynamic changes in 
residual beta-cell function. Serial 
measurements of stimulated C-peptide which 
directly reflect residual beta-cell function 
have therefore become the gold  standard for 
evaluation of endogenous insulin secretion 
(13) but no definitions of PR has been 
proposed  based on stimulated C-peptide. 
Besides, determination of stimulated C-
peptide is a laborious, expensive and time 
consuming research tool and unpleasant for 
the child. The patient has to present fasting, 
take part in a 90 minute study and delay the 
morning insulin.  Therefore, it would  be 
useful to have an easy clinical measure for the 
PR  somewhat similar to the homeostasis 
model assessment (HOMA) for insulin 
resistance and beta-cell function (14). The 
objective of the current longitudinal 
investigation was therefore to evaluate the 
relation between HbA1c and insulin dose, 
which are both routinely measured in clinical 
practice, to create a surrogate measure of 
stimulated C-peptide and near normal 
glycemia. Furthermore the study aimed to 
examine the validity and reliability of this 
measure.  
 
RESEARCH DESIGN AND METHODS 
Study subjects: The study was a 
multicentre longitudinal investigation in 18 
paediatric departments representing 15 
countries in Europe and Japan. 275 children 
and adolescents less than 16 years with newly 
diagnosed type 1 diabetes presenting to the 
paediatric departments between August 1999 
and December 2000, were included in the 
study.  Exclusion criteria were: suspected 
C 
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non-T1D (MODY, secondary diabetes etc.), 
and patients initially treated outside of the 
centres for more than 5 days.  Patients were 
diagnosed according to the World Health 
Organization (WHO) criteria. Eighty-four  
percent of the patients were white Caucasian, 
and the mean ± SD age at clinical diagnosis 
was 9.1 ± 3.7 yrs; body mass index, 16.5 ± 
3.2 kg/m2; insulin regimens were recorded 1, 
3, 6, 9 and 12 months after diagnosis. After 
12 months 52.9% of the children were on 
twice insulin daily, 25% on three times and 
18.5% on 4 or more injections. Only a few 
children (3.3%) received one insulin injection 
daily. A premixed form of insulin was used in 
72.3 % of the children on twice daily insulin. 
Only 3 children used an insulin infusion pump 
while 13% were treated with a rapid acting 
insulin analogue. Mean daily insulin dose: 0.7 
±0.3 U/kg.  In order for the new measure to 
cover different insulin policies local centres 
were not instructed to follow a specific insulin 
treatment program.   
 The study was performed according to the 
criteria of the Helsinki II Declaration (15) and 
was approved by the local ethical committee 
in each centre. All the patients, their parents 
or guardians gave informed consent.   
Methods: HbA1c - Samples for 
HbA1c analysis were collected at onset and 
after 1, 3, 6, 9 and 12 months at each 
department using the Bio-Rad HbA1c sample 
preparation kit (Bio-Rad Laboratories, 
Munich, Germany) and mailed to the Steno 
Diabetes Centre (Denmark) as described 
before (16). The HbA1c analysis was 
performed by automatic high-pressure liquid 
chromatography with the same calibrator lots 
as used in the DCCT to facilitate comparisons 
with this study.  Normal range for HbA1c for 
the method at Steno Diabetes Center was 4.4 
– 6.3 % (about 0.3 % higher than the DCCT 
method). 
C-peptide - After 1, 6, and 12 month 
of diabetes, a standard liquid meal was 
utilized to stimulate endogenous C-peptide 
release (17). Serum samples were labelled and 
frozen at – 20 °C until shipment on dry ice to 
Steno Diabetes Centre for the determination 
of C-peptide within ½ year. Samples were 
thawed only once for RIA determination. 
Serum C-peptide was analyzed by a 
fluoroimmunometric assay (AutoDELFIATM 
C-peptide, PerkinElmer Life and Analytical 
Sciences, Inc, Turku, Finland). The analytical 
sensitivity was better than 5 pmol/l, intra-
assay coefficient of variation below 6 % at 20 
pmol/l, and recovery of standard, added to 
plasma before extraction, about 100 % when 
corrected for losses inherent in the plasma 
extraction procedure. 
Statistics: HbA1c and insulin dose 
cannot be considered separately as the measured 
HbA1c will be influenced by the insulin dose as 
well as by the residual beta-cell function. The idea 
was to combine the two in order to suggest a new 
measure of insulin-dose adjusted HbA1c (IDAA1c) 
being relatively less influenced by treatment 
policy. A unified suggestion, in which both  
HbA1c and insulin dose were included, was 
investigated by multiple regression analysis with 
the logarithm of stimulated C-peptide as the 
dependent variable and gender, age,  HbA1c and 
daily insulin dose (U/kg bodyweight) as 
independent variables  6 and 12 months after 
diagnosis.  
In the DCCT trial a limit of 300 
pmol/l was defined as the level for “the C-
peptide responders” (200-500 pmol/l). We 
aimed at defining PR in alignment with the 
DCCT (17) as an IDAA1c predicting a C-
peptide response of  >300 pmol/l.  
To investigate the influence of age on the 
proportion in remission the insulin 
requirement and HbA1c values during the 
follow-up were analysed with the patients 
divided into age groups (0-4.9, 5.0-9.9, 10.0-
16yrs). Age group comparisons versus 
IDAA1c ≤ 9 was done by Chi-Square test for 
the count of patients. 
To compare the various definitions the 
proportion of children in PR as defined by 
each definition was evaluated at 3, 6, 9 and 12 
© 
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months. The insulin dose used to calculate the 
rate of PR was the value before the visit 
because HbA1c reflects the blood glucose 
level over the previous 4 to 6 weeks period 
(8).  
A statistical comparison was 
conducted to evaluate the concurrent 
agreement of HbA1c, IDAA1c, and 
stimulated C-peptide. Agreement between the 
definitions was examined by plotting twelve 
months values for stimulated C-peptide 
against both HbA1c and IDAA1c and with 
summary statistics for percentage agreement 
with stimulated C-peptide. This was 
supplemented with a formal Chi-Square test 
of which parameters  HbA1c or IDAA1c that 
are most closely related to C-peptide, by 
constructing the 2 by 2 by 2 table of 
classifications based on  HbA1c, IDAA1c and 
stimulated C-peptide. In this table, it was 
tested whether HbA1c ≤ 7.5 or >7.5 had an 
influence on stimulated C-peptide, when the 
IDAA1c classification was included. This 
consists for each IDAA1c group (≤ 9, 
respectively >9) a test of independence of 
HbA1c group and stimulated C-peptide 
group. A similar test was done with HbA1c 
and IDAA1c with reversed roles. The two test 
statistics were then added to obtain a joint 
conclusion which of the two measures gives 
the best agreement with the C-peptide 
definition.  
To confirm the validity of IDAA1c at 
12 months duration the relationship of 
stimulated C-peptide and IDAA1c at 6 and 12 
months was investigated by linear regression 
according to duration and IDAA1c but not 
gender and age.  
To examine the predictive validity of 
IDAA1c, HbA1c and insulin dose data from 1 
and 6 months were used in a multiple 
regression model (including covariates age 
and gender) to predict C-peptide responses 
(logarithmic scale) at 6 and 12 months, 
respectively.  
To examine the agreement between 
the two definitions (IDAA1c ≤ 9%  and 
stimulated C-peptide > 300 pmol/l) a Chi-
Square test was performed in the 2 by 2 table 
of classifications based on  IDAA1c and 
stimulated C-peptide. 
The stability of the IDAA1c defined 
PR was investigated by comparing the 
number of subjects transiting into and out of 
PR defined by IDAA1c and by other 
definitions of PR over the period 6 to 12 
months. 
Statistical analyses were performed 
using SAS version 9.1 (SAS Institute, USA, 
Inc, Cary, NC, USA). A p-value of 0.05 or 
less was considered significant.  
 
RESULTS 
Partial remission defined by 
IDAA1c: The multivariate analysis showed a 
negative correlation between stimulated C-
peptide, HbA1c and insulin dose, with a 
significant effect of age (estimate 0.09/year, 
p<0001) but not gender (estimate comparing 
females to males -0.01, p=0.91) at 6 months 
after diagnosis. It would be natural to include 
an age effect in the formula, if the aim of the 
study had purely been to predict the 
stimulated C-peptide level. However, as the 
purpose was to suggest a new measure for 
remission it was anticipated that the suggested 
formula for IDAA1c could be useful on its 
own and therefore age was not included. 
From the regression coefficients at six 
months:  HbA1c –0.21 and insulin dosage –
0.94 it was seen that there was a factor of 
about 4.4 between the coefficients for these 
parameters. The R2 value was found to be 
0.30. Results at six and 12 months were 
similar. This inspired the suggestion of a 
combined expression of insulin dose and 
HbA1c, formulated as a specific definition of 
the insulin dose-adjusted HbA1c (IDAA1c) = 
HbA1c (%) + 4 x [insulin dose (U/kg/24h)]. 
The factor of 4.4 was substituted by 4 to 
obtain simple numbers. Based on the slope of 
© 
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the regression line between stimulated C-
peptide, HbA1c and insulin dose a predicted 
C-peptide can be calculated from any given 
set of corresponding HbA1c and insulin dose. 
The distribution of patients according to 
individual HbA1c and insulin dosages at 6 
months duration are shown in Figure 1A, in 
which each diagonal red line correspond to 
one IDDA1c value. According to this model 
an IDAA1c threshold ≤ 9 correspond to a 
predicted level of >300 pmol/l for the 
corresponding stimulated C-peptide. This 
expression can be used as a qualitative 
measure of PR and in alignment with the 
DCCT “C-peptide responders” (200-500 
pmol/l) we have chosen IDAA1c ≤ 9 to define 
PR. Other threshold values for IDAA1c could 
have been chosen corresponding to different 
predicted C-peptide values. Compared to the 
PR definition: insulin dose ≤ 0.5 U/kg/24 and 
HbA1c ≤ 7.5% (rectangular dashed box), our 
definition has been extended with the 
triangular area above and to the right side of 
the dashed rectangle (Figure 1A). As an 
indicator of more aggressive insulin therapy 
at some of the centres, there are more cases 
placed in the  triangle to the right of the 
dashed line that marks an insulin dose ≤ 0.5 
U/kg/24h than in the upper triangle above the 
dashed line marking an HbA1c ≤ 7.5%.  
Partial remission by IDAA1c and 
influence of age: Figure 1B shows that age at 
onset influences the rate of PR in children 
with type 1 diabetes. Significantly (p< 0.05) 
fewer patients in the young age group (0-5 
yrs) were in PR (3-9 months, p<0.01) 
compared to the older age groups. After 12 
months only 5% of the very young children 
are in PR compared to 20% of the older age 
groups. 
Comparison of partial remission by 
IDAA1c with existing definitions: The 
proportion of children in PR according to 
various definitions is shown in Figure 1C as a 
function of diabetes duration. As the HbA1c 
level at one month still reflects glycemia 
before diagnosis the comparison between the 
different definitions of PR was performed at 3 
months.  From 3 to 12 months the curves for 
IDAA1c (Curve 1), C-peptide (Curve 2) and 
insulin dose (Curve 4) show close agreement. 
The definition of PR including insulin dose ≤ 
0.5 U/kg/24h and HbA1c ≤ 7.5% (Curve 5) 
suggests that fewer are in PR and HbA1c ≤ 
7.5% without insulin dose adjustment (Curve 
3) suggests that more patients are in PR after 
3 months. Using the new definition, PR 
occurred in 61% at 3 months, in 44 % at 6 
months and 18% after 12 months. 
Agreements between HbA1c, 
IDAA1c, and stimulated C-peptide: The 
agreement between definitions of those in PR 
by  HbA1c ≤ 7.5% and by IDAA1c ≤ 9 
compared to residual beta-cell function with 
C-peptide >300 pmol/l, are shown in figure 
1D. The definitions agree in the upper left 
quadrant and the lower right quadrant of the 
diagrams. However, for HbA1c (left panel) 
there are significantly more patients in the 
lower left quadrant of the diagram with an 
HbA1c ≤ 7.5% but with a residual beta-cell 
function ≤ 300 pmol/l than for IDAA1c (right 
panel), probably because the aggressively 
insulin treated children with low residual 
beta-cell function are more accurately 
accounted for in the dose adjusted model (see 
formal Chi-Square test below). A formal test 
of the strength of the relationship between 
each definition and stimulated C-peptide at 6 
months, was performed in a model, where the 
classifications of PR according to both 
HbA1c and IDAA1c were allowed an effect 
on the C-peptide definition of PR (>300 
pmol/l).  
In the joint test, HbA1c was not 
significant (chi-square=2.40, 2 degrees of 
freedom, p=0.30), whereas IDAA1c was 
clearly significant (chi-square=11.07, 2 
degrees of freedom, p=0.004).Thus IDAA1c 
gives the best agreement with the C-peptide 
definition. The same conclusion was reached 
after 12 months. 
© 
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Correlation between IDAA1c and 
actual C-peptide response at 6 and 12 
months: The relationship of IDAA1c and 
stimulated C-peptide at 6 and 12 months is 
shown in Figure 1 E. The regression curves 
suggest a tendency towards higher stimulated 
C-peptide values at 6 months compared to 12 
months, also when related to IDAA1c. 
Overall, the predictive value of IDAA1c in 
combination with gender and age was good 
(R2 0.30 at 6 months, and 0.31 at 12 months) 
IDAA1c at 1 and 6 months as 
predictor of future values of C-peptide 
response: Predicting C-peptide after 6 
months based on one month data, as well as 
after 12 months based on 6 month data, using 
gender, age, HbA1c and insulin dose, it was 
found that there was a significant dependence 
on both HbA1c and insulin dose, but the 
effect of these could be adequately 
summarized by the IDAA1c. The coefficients 
in the final model for predicting (log) C-
peptide after 12 months was gender (estimate 
for females -0.11, p=0.40), age (estimate 0.13, 
p<0.001) and IDAA1c after 6 months 
(estimate -0.32, p<0.001). 
Stability of IDAA1c defined PR in 
the prepubertal compared to older age 
groups: Only a few of the very young 
children (0-4 years) are in PR using any of the 
two definitions (stimulated C-peptide >300 
pmol/l or IDAA1c ≤ 9). The older children 
(10-16 years) have relatively higher C-peptide 
values, thus the patients, who are in PR 
according to C-peptide, but not IDAA1c are 
mostly older presumably with more insulin 
resistance due to puberty, whereas those that 
are not in PR according to C-peptide, but in 
PR according to IDAA1c are in the 
prepubertal group (5-9 years) with better 
insulin sensitivity. The two definitions agree 
for 71.4 % of the prepubertal and the older 
group of patients (average for 6 and 12 
months values) 
Stability of the definitions: During 
the period 6 to 12 months after diagnosis, the 
change in frequency of PR as assessed by  
IDAA1c,  HbA1c,  insulin dose and 
stimulated C-peptide , is illustrated in Table 1. 
Using the IDAA1c ≤ 9 only 1 patient entered 
PR and 61 ended PR; using  HbA1c ≤ 7.5 %, 
15 entered PR and 53 ended; using insulin 
dose ≤ 0.5 U/kg/24h  5 entered and  66 ended 
and using stimulated C-peptide (>300 pmol/l) 
9 entered PR and 49 ended. 
 
CONCLUSIONS 
We have suggested a novel definition:  
HbA1c (%) + [4 x insulin dose (U/Kg/24h)] ≤ 
9 for the PR period in children and 
adolescents with type 1 diabetes (Figure 1 A). 
This practical and simply calculated definition 
is useful as it relates insulin dose and 
measured HbA1c to the preservation of beta-
cell function (C-peptide levels). This measure, 
adjusting for the exogenous insulin, can be 
used as a quantitative measure of the 
underlying and theoretically untreated disease 
and it is in this setting superior to a definition 
using HbA1c alone.  
This definition also avoids the 
necessity of measuring C-peptide levels, 
which is laborious, expensive and often 
unavailable. Generally, there is good 
agreement between these two measures 
IDAA1c and C-peptide (Figure 1 C), although 
we see a different pattern over age (Figure 
1B,E), as discussed below. Using either 
HbA1c ≤ 7.5% or IDAA1c ≤ 9 the maximum 
PR in all age groups is reached at around 3 
months after diagnosis (Figure 1B), which is 
in accordance with other studies (11,18). In 
addition, the IDAA1c correctly identifies 
those in PR from the very start whereas a PR 
definition by insulin dosage ≤ 0.5U/kg/24h 
misclassifies a proportion early in the disease 
due to lack of or delay in insulin treatment 
around the time of diagnosis (Figure 1C). 
This may be of importance for selection of 
patients into intervention studies aimed at 
protecting islet cell function.  
© 
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Because IDAA1c is based on a joint 
evaluation of  C-peptide, HbA1c and insulin 
dose, the agreement of those in PR by the C-
peptide definition is better for IDAA1c than 
for HbA1c alone (Figure 1D) which was also 
shown in the chi-square test of the 
relationship between the two measures and 
stimulated C-peptide.  
Interestingly, the residual beta cell 
function was highest in the age group 10-15 
yrs during the whole study period and this is 
comparable with the observations of the US 
multicenter national study group Type 1 
diabetes Trial Net (13). Despite this, the new 
definition indicates that the frequency of PR 
was not higher in this group of patients 
compared to the school age children 5-10 yrs 
old. Likewise the mean daily insulin dose was 
higher in the older age group (10-15 yrs) than 
in the younger (5-10 yrs) perhaps indicating 
higher insulin resistance during puberty (19). 
Thus the degree of hyperglycemia is not 
determined only by the beta-cell function or 
insulin resistance but results from a 
combination of these two factors which is 
reflected in the new definition. Therefore 
IDAA1c was in agreement with stimulated C-
peptide in 71.4 % of those in PR of the 
prepubertal and older patients (1E)  
 It is important to know the 
relationship of IDAA1c and stimulated C-
peptide during the first year in new onset type 
1 diabetes. Overall IDAA1c showed a good 
correlation with the residual beta cell function 
as assessed by stimulated C-peptide (R2 31%). 
This agreement level compares well with the 
homeostasis model assessment (HOMA) (14) 
where  estimates of  beta-cell function 
correlated with hyperglycaemic clamp (37%) 
and to the intravenous glucose tolerance test 
(41%) . In addition IDAA1c at 6 months was 
the best predictor of stimulated C-peptide 
concentrations at 6 and 12 months compared 
to HbA1c and insulin dose. This shows that 
IDAA1c overall is a good estimate of 
stimulated C-peptide in type 1 diabetes. 
In terms of stability over time, only 
one patient was found to enter PR between 6 
and 12 month duration. When spontaneous 
PR occurs in pre-pubertal or pubertal patients, 
it occurs most often  within the first 4 months, 
and infrequently after 6 months (20,21). This 
is a strong endorsement of the new IDAA1c 
definition as all other definitions discussed 
have higher number of patients that appear to 
enter PR in the period 6 to 12 months (Table 
1).  
The new formula is very easy and 
practical to use in the daily clinic where a 
diabetes nurse specialist takes care of many 
aspects of daily management, during the first 
months after diagnosis. At each visit in the 
outpatient clinic the IDAA1c can be 
calculated by the nurse to check that the 
patient is still in remission particularly if they 
do not frequently measure blood glucose or 
record data. If this is not the case the patient 
may need to be referred to a pediatric 
diabetologist for changes in insulin 
management. Already this has improved the 
delivery of diabetes care in some of our 
clinics and leads to a smooth transition to 
more individual treatment regimens.  
Direct measurement of C-peptide has 
been recommended to provide the most 
appropriate primary outcome in trials 
evaluating the efficacy of therapies to 
preserve beta-cell function (13). The new 
IDAA1c should be beneficial for research in 
this area as it might remove the need for 
intrusive investigations. It takes into account 
the glycemic consequences of a change in 
residual beta cell function.  C-peptide 
measurements alone do not provide this 
information. In addition the model should 
make it easier to select children and 
adolescents with a significant endogenous 
insulin production and evaluate clinically 
meaningful changes in intervention therapies 
(22) that are aimed at preserving/regenerating 
beta cell function in new onset type 1 
diabetes.   
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In conclusion, the new insulin dose 
adjusted definition of the partial remission 
period gives the best agreement with the 
stimulated C-peptide definition, is convenient 
and easy to use and is associated with a 
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Table 1: PR transitions from 6 to 12 months 
Number of patients according to PR status at 6 and 12 months (per cent among patients 
according to state at 6 months).  
 
 In PR at 6 months Not in PR at 6 months 
PR definition Proportion in PR at 12 months Proportion in PR at 12 months 
IDAA1c ≤ 9 % 37/98 (38%) 1/122 (1%) 
HbA1c ≤ 7.5 % 87/140 (62%) 15/85 (18%) 
Insulin dose ≤ 0.5 U/kg/24h 46/112 (41%) 5/123 (4%) 
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Figure 1A  
The thresholds for PR remission based on IDAA1c ≤ 9 (solid green line) and HbA1c ≤ 7.5 % and 
insulin dosages ≤ 0.5 U/kg/24h (rectangular dashed box). Each diagonal red line correspond to 
one IDAA1c value. The numbers in boxes are the predicted values for stimulated C-peptide 
concentrations for a ten-year old boy at the relevant IDAA1c value and as illustrated other 
thresholds values for IDAA1c correspond to different predicted C-peptide values.  The + signs 
give the distribution of 257 cases of type 1 diabetes after 6 months duration.  
 
Figure 1B. 
Age at onset influences the rate of PR as assessed by IDAA1c in children with type 1 diabetes.  
The proportion of PR is lowest in the youngest age group (0-4.9 years). Due to lower insulin 
sensitivity the proportion of PR in the old age group (≥10 years) and the school age children (5-
9.9 years) appears similar despite higher residual beta cell function.  
 
Figure 1C 
The proportion of children in PR according to the different definitions. From 3 to 12 months the 
curves for IDAA1c (Curve 1), C-peptide (Curve 2) and insulin dose (Curve 4) show close 
agreement.Using the new definition, PR occurred in 61% at 3 months, in 44 % at 6 months and 
18% after 12 months. 
 
Figure 1D 
The agreement between definitions of those in PR, HbA1c ≤ 7.5% (left panel, dashed vertical 
line), IDAA1c ≤ 9 (right panel, dashed vertical line) and stimulated C-peptide >300 pmol/l 
(dashed horizontal line) at 12 months. The arrows point to the areas showing that HbA1c ≤  7.5 
disagree significantly more than IDAA1c ≤ 9 with the C-peptide >300 pmol/l probably because 
the children receive more exogenous insulin which is accounted for in the insulin dose adjusted 
model.     
 
Figure 1E   
The relationship of IDAA1c ≤ 9 (dashed vertical line) and stimulated C-peptide >300 pmol/l 
(dashed horizontal line) at 6 and 12 months. Individual observations are shown by age groups. 
The regression lines 6 (solid) and 12 (dashed) months show the linear correlation of IDAA1c and 
C-peptide over a continuum of stimulated C-peptide values.  
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